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1. Introduction 
Urinary tract infections (UTIs) can be classified as either uncomplicated or complicated.  
Uncomplicated UTIs occur mostly in young women who are sexually active and who have 
normal genitourinary anatomy. These patients usually have had no previous risk factors 
otherwise, and no previous surgeries or manipulation of the genital tract.  This chapter will 
discuss the epidemiology, pathogenesis, infecting organisms, clinical manifestations, 
diagnosis, treatment, and prevention of uncomplicated UTIs. 
2. Epidemiology 
UTIs are one of the most common infections caused by bacteria.  UTIs account for more than 
8 million doctor’s visits each year in the U.S. These infections generate more than 3 million 
prescriptions, and costs an estimated $3.5 billion dollars annually to treat (University of 
Michigan Health System, 2010) 
UTIs occur more frequently in women than in men, and will occur in roughly half of women 
during their lifetime.  In men, decreased urinary flow from enlarged prostates increase the 
risk of infection. (University of Michigan Health System, 2010) 
3. Pathogenesis 
The urinary system includes the kidneys, ureters, bladder, and the urethra (Figure 1).  This 
system removes body waste; specifically, urea, from the blood. Urea is carried in the 
bloodstream to the kidneys. The kidneys extract urea from the blood through filtering units 
called nephrons. Urea, along with other waste products and water, forms the urine. Urine 
then passes through the kidneys, to the ureters. From the ureters, urine flows into the 
bladder. The bladder collects urine and, intermittently, it passes out of the bladder into the 
urethra, which is a tube that excretes urine from the body. 
Many different problems can occur within the urinary tract. Aging can decrease the action 
of muscles within the urinary system and decrease excretion of urine; therefore, urine may 
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back up and an infection can develop.  Injuries from trauma or surgery can also cause 
infection.  In addition, other illnesses and medical conditions can predispose decreased 
emptying of urine, which can then predispose to infection.  These illnesses include prostatic 
enlargement in elderly men, diabetes mellitus, nephrolithiasis (kidney stones), and other 
neurologic conditions that can also cause a neurogenic bladder.  Manipulation and 
instrumentation such as insertion of urinary catheters can cause UTIs. 
 
 
Fig. 1. Urinary System. 
Usually, the urinary tract is able to eliminate harmful bacteria.  High urine osmolarity and 
acidity inhibit the growth of most pathogens in the urine. However, these same 
characteristics can also decrease white blood cells’ effectiveness in clearing infection.  As 
such, these urinary characteristics, despite being a noxious environment for bacteria to 
thrive, can also lower resistance to infections by rendering white blood cells less effective. 
(Alonto, 2007) 
Bacteria can enter the urinary tract through two main routes: ascending route and 
hematogenous route. The most common way to develop UTI is via the ascending route.  
Bacteria can enter the urinary tract through the urethra.  From the urethra, bacteria can then 
ascend into the bladder, ureters, and kidneys.  Infection of the kidneys is called 
pyelonephritis. (Alonto, 2007) 
Hematogenous route of infection can occur in patients who have bacteremia from other foci 
of infection such as endocarditis.  The pathogenic bacteria that enter the blood stream can 
then infect the renal parenchyma, causing pyelonephritis, and even renal abscesses. 
UTIs are most commonly caused by bacteria that enter the bladder through the urethra.  The 
genitourinary anatomy of women predisposes them to UTIs.  Their urethras are shorter, and 
closer to the anus, providing easier access for fecal bacteria to enter the urethra. This is the 
major reason women experience infections significantly more frequently than men.   
Many other conditions can increase the chances of developing UTIs.  These conditions 
include menopause, diabetes, advanced age, kidney stones, pregnancy, and urinary tract 
instrumentation.  In men, prostatic hypertrophy blocks the flow of urine and, because of 
this, there is also increased chance of developing UTIs in men with this condition. 
Table 1 explains the most common terms used for urinary tract infections. 
www.intechopen.com
 A Review of Uncomplicated Urinary Tract Infections 
 
5 
Urinary tract infection 
Microbial (bacterial, viral, fungal, etc.) infection 
that affects any part of the urinary tract 
Lower urinary tract infection Infection of either the bladder or the urethra. 
Upper urinary tract infection 
Although the upper urinary tract is composed of 
the kidneys and ureters,  upper urinary tract 
infection generally affects the kidneys  
Pyelonephritis Infection affecting the kidneys 
Cystitis Infection affecting the bladder 
Urethritis 
Infection affecting the urethra.  Common 
pathogens causing urethritis include Chlamydia 
trachomatis and Neisseria gonorrhoeae 
Cervicitis 
Infection affecting the cervix.  Mostly due to 
pathogens causing sexually transmitted diseases 
such as Chlamydia trachomatis and Neisseria 
gonorrhoeae 
Prostatitis Infection of the prostate 
Renal abscess 
Infection of the renal parenchyma which forms 
purulent collection within or around the renal 
parenchyma 
Bacteruria 
Presence of bacteria in the urine. Does not 
necessarily indicate presence of infection. Does 
not need to be treated in most instances, if patient 
is asymptomatic. 
Pyuria 
Presence of white blood cells in the urine.  
Indicates inflammation, not necessarily from 
infection. 
Table 1. Terms Used for Specific Urinary Tract Infections. 
4. Infecting organisms 
Uropathogens have characteristics that enable them to be successful in causing infections of 
the urinary tract. Adhesins enable the attachment to host membranes. Capsular 
polysaccharides, hemolysins, cytotoxic necrotizing factor (CNF) protein, and aerobactins are 
other factors that enable uropathogens to invade the urinary tract. Table 2 lists common 
virulence factors associated with pathogens causing UTIs. (Brusch, 2010) 
 
Virulence Factors 
Adherence 
Calculi formation 
Toxin production 
Lipopolysaccharides 
Capsular polysaccharide 
Hemolysins 
Biofilm 
Aerobactins 
Table 2. Virulence Factors in Uropathogens. 
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The most common pathogen causing UTIs is Escherichia coli (E. coli), causing 70-95% of 
urinary tract infections.  Other organisms that can be responsible for UTIs include Gram-
positive cocci, such as Staphylococcus saprophyticus and Enterococcus faecalis.  Other Gram-
negative organisms responsible for causing UTIs include Klebsiella species and Proteus 
species.  Hospitalized patients can develop complicated UTIs, and more common organisms 
isolated in these infections include Gram-negative organisms such as Pseudomonas 
aeruginosa, Enterobacter species, and Acinetobacter species; Gram-positive organisms 
including Staphylococcus aureus; and even yeast.  Table 3 lists organisms that can be seen in 
urinary tract infections. (Brusch, 2010) 
 
Pyelonephritis 
Gram-positive Bacteria 
Staphylococcus aureus 
Staphylococcus saprophyticus 
Gram-negative Bacteria 
Escherichia coli 
Klebsiella species 
Proteus species 
Pseudomonas aeruginosa 
Enterobacter species 
Cystitis 
Gram-negative Bacteria 
Escherichia coli 
Klebsiella species 
Proteus species 
Gram-positive Bacteria 
Staphylococcus saprophyticus 
Enterooccus species 
Staphylococcus aureus 
Urethritis 
Chlamydia trachomatis 
Neisseria gonorrhoeae 
Ureaplasma urealyticum 
Table 3. Organisms Associated with Urinary Tract Infections. 
5. Clinical manifestations 
The clinical manifestations of UTIs can vary significantly, especially in the extremes of age.  
UTIs in children can present with different symptoms.  Symptoms in children younger than 
2 years of age tend to be nonspecific, and can include fever, vomiting, and failure to thrive. 
In contrast, the elderly patient who has a UTI may be asymptomatic.  When symptoms are 
present, they can include abdominal pain or mental status changes.   
However, the classic symptoms of acute uncomplicated cystitis include dysuria, change in 
urinary frequency, urinary urgency, hematuria, and suprapubic pain.  Fever is usually 
absent in those with lower UTIs. 
In general, acute uncomplicated pyelonephritis classically presents with flank pain, 
abdominal pain, nausea, vomiting, fever, and costovertebral angle tenderness.  Symptoms of 
cystitis may or may not be present in those with pyelonephritis.  When present, these signs 
can occur 24-48 hours prior to appearance of symptoms of pyelonephritis.  Some patients 
with acute pyelonephritis can present with sepsis. 
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6. Diagnosis 
There are many different etiologies, both infectious and non-infectious, that can present 
with acute dysuria.  The differential diagnosis of acute dysuria may include pyelonephritis, 
cystitis, urethritis, infectious vaginitis, atrophic vaginitis, and interstitial cystitis.  A good 
history and physical examination usually gives the clinician enough information to make a 
correct diagnosis in most situations.   
 
Acute cystitis  
Acute pyelonephritis  
Urethritis  
 
Chlamydia trachomatis 
Neisseria gonorrhoeae 
Trichomonas vaginalis 
Candida albicans 
Herpes simplex virus 
Irritant urethritis 
Vaginitis  
 
Candida albicans 
Trichomonas vaginalis 
Bacterial vaginosis 
Atrophic vaginitis 
Interstitial cystitis  
Table 4. Differential Diagnoses of Acute Cystitis. 
The most valuable diagnostic test for UTI is a urine analysis.  The preferred definition of 
pyuria is at least 10 leukocytes/mm3 of midstream urine by counting changer.  Using this 
definition, the majority of patients with bacteruria will have pyuria as well.  Pyuria is 
present in almost all patients with acute cystitis.  If pyuria is not seen, an alternative cause 
for the patient’s symptoms will need to be considered. (Brusch, 2010) 
Urine dipstick is a rapid screening test for detecting pyuria, as it can detect the presence of 
leukocyte esterase.  The urine dipstick also detects nitrite, which signifies the presence of 
Enterobacteriaceae, bacteria which convert nitrite to nitrate. Although the nitrite test is a 
sensitive test for detecting Enterobacteriaceae, it may not detect other pathogens. (Brusch, 
2010) 
Urine in the bladder is sterile.  However, because the urethra is usually contaminated 
with bacteria, collected urine specimens are frequently not sterile. A midstream, clean-
voided urine, can separate contamination from urinary tract infection. Urine specimens 
from most patients with UTIs should have at least 105 bacteria/mL. Patients without 
infection should have less than 104 bacteria/mL. However, there are some patients  
with urinary infections that have fewer than 105 bacteria/mL in urine. (Sobel & Kaye,  
2005) 
The Infectious Diseases Society of America consensus definition of cystitis for use in 
antibiotic treatment studies is 103  bacteria/mL or more of an uropathogen, and for 
pyelonephritis 104  bacteria/mL.   
Acceptable methods for urine collection include midstream clean catch, catheterization, and 
suprapubic aspiration. (Sobel & Kaye, 2005) 
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7. Treatment 
Because overuse and abuse of antimicrobial agents has led to rapidly evolving resistance of 
pathogens to this precious class of medications, appropriate administration of antibiotics to 
treat UTIs cannot be overemphasized. Appropriate use of antibiotics include correct 
indications, correct choice of antibiotic(s) (according to local resistance data or culture data), 
and timely administration of the agent(s) with appropriate dosage and treatment duration.  
7.1 Asymptomatic bacteriuria (Alcaide & Lichtstein, 2004) 
This condition is defined by the presence of more than 105 bacteria/mL in the urine of a 
patient without urinary tract and/or constitutional symptoms. Antibiotic treatment for 
asymptomatic bacteriuria is not indicated unless the woman is pregnant or the patient is 
about to undergo a urologic procedure, e.g. cystoscopy. Prescribing antibiotics in patients 
with asymptomatic bacteriuria exposes them to potential adverse drug reactions, such as 
development of C. difficile infection and increased selective pressure leading to the 
development of antimicrobial resistance. Unfortunately, despite data not supporting the 
prescription of antibiotics to patients with asymptomatic bacteriuria, many clinicians 
administer antibiotics to this group of patients based on individual habit or convention 
rather than clinical evidence or guidelines.  
7.2 Acute uncomplicated cystitis (AUC) 
As described in the section “Infecting Organisms”, the most common etiologic agent of AUC 
is E. coli. Other common pathogens are S. saprophyticus, E. faecalis, Klebsiella species and 
Proteus species. The selection of antibiotics should target the above common pathogens.    
The following is a detailed description of commonly used antibiotics recommended for 
treating AUC (Mascaretti, 2003a; Dielubanza & Schaeffer, 2011; Gupta et al., 2011). 
7.2.1 Nitrofurantoin monohydrate/macrocrystals 
Nitrofurantoin is reduced by bacterial flavoproteins to highly reactive intermediates which 
are active in damaging the DNA of susceptible bacteria. Most stains of E. coli, S. 
saprophyticus and Enterococcus species are sensitive to nitrofurantoin. However, most species 
of Proteus and Klebsiella are less susceptible to this drug.  
Nitrofurantoin is indicated for the treatment of AUC only. Because it is eliminated without 
achieving antibacterial concentration in plasma or tissues, nitrofurantoin is not indicated for 
treating pyelonephritis. Because the rate of excretion of nitrofurantoin is linearly related to 
creatinine clearance, impaired renal function may decrease its efficacy and increase systemic 
toxicity of the drug (Petri, 2006).  
Common side effects of nitrofurantoin are nausea, vomiting and diarrhea. However, the 
macrocrystal form appears to have lower gastrointestinal adverse reactions. Insidious 
irreversible interstitial pulmonary fibrosis can develop in elderly taking nitrofurantoin 
chronically. Therefore, patients who are taking this drug long term should undergo 
pulmonary function tests and chest radiography periodically.   
Gupta et al. demonstrated that a 5-day course of nitrofurantoin is equivalent, clinically and 
microbiologically, to a 3-day course of trimethoprim-sulfamethoxazole (Gupta et al., 2007). 
The 2011 updated IDSA guidelines for uncomplicated urinary tract infection also 
recommended using nitrofurantoin monohydrate/macrocrystals 100 mg by mouth twice 
daily for 5 to 7 days (Gupta et al., 2011).   
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7.2.2 Trimethoprim/sulfamethoxazole (TMP/SMX) 
TMP/SMX inhibits bacterial DNA, RNA and protein synthesis by interfering with folic acid 
synthesis. TMP/SMX’s spectrum will cover E. coli and S. saprophyticus, the two most 
uropathogens in causing AUC. TMP/SMX has excellent tissue penetration, so it can be used 
to treat upper urinary tract infection, including uncomplicated pyelonephritis.  
Skin rash and gastrointestinal adverse reactions; including nausea, vomiting, and anorexia 
are the common side effects of TMP/SMX.  The dose should be reduced in patients with 
renal impairment. 
TMP/SMX 160/800mg (double strength tablets) by mouth twice daily for 3 days is the 
recommended regimen for empirical treatment of AUC, provided the local community 
resistance prevalence of common uropathogens to TMP/SMX is less than 20%.  
7.2.3 Fosfomycin trometamol 
Fosfomycin inhibits bacterial cell wall synthesis by irreversibly inactivating the enzyme 
pyruvoyl transferase, an enzyme crucial in the synthesis of cell walls by bacteria.  
Fosfomycin exhibits a broad spectrum of activity against Gram positive and gram negative 
bacteria including E. coli and P. mirabilis (Mascaretti, 2003b). 
Fosfomycin is well tolerated. Common side effects are headache, diarrhea and nausea.  
In a multicenter clinical trial comparing single-dose fosfomycin with a 7-day course of 
nitrofurantoin for the treatment of AUC in female patients, Stein showed that bacteriologic 
and clinical cure rates of a single 3-g dose of fosfomycin and 7-day course of nitrofurantoin 
were comparable (Stein, 1999). Minasssian et al. from The United Kingdom also 
demonstrated that a single dose of 3g of fosfomycin trometamol had a comparable 
microbiological cure rate and was similar to a 5-day course of trimethoprim (Minassian et 
al., 1998).   Fosfomycin is approved as a single dose of 3g powder mixed with water to treat 
AUC.  
7.2.4 Fluoroquinolones  
The fluoroquinolones inhibit relaxation of supercoiled DNA and cause breakage of DNA 
strands by inhibiting DNA gyrase and topoisomerase IV in susceptible bacteria.  
The fluoroquinolones that are commonly used to treat AUC are ciprofloxacin and 
levofloxacin. Both offer excellent coverage for Gram positive and Gram negative bacteria 
including Enterobacteriaceae. Common side effects of ciprofloxacin and levofloxacin are 
headache, nausea, diarrhea, abdominal pain and constipation. A rare complication may be 
Achilles tendon rupture in elderly patients.  
Arredondo-Garcia et al. conducted a randomized, multicenter, open-label, prospective 
study to compare the bacteriologic and clinical efficacy of  oral ciprofloxacin 250mg twice 
daily for 3 days vs oral trimethoprim/sulfamethoxazole 160/800mg twice daily for 7 days 
vs oral norfloxacin 400mg twice daily for 7 days for treatment of AUC. The authors were 
able to show that a 3-day regimen of oral ciprofloxacin was clinically and bacteriologically at 
least as effective as a 7-day course of TMP-SMX and norfloxacin (Arredondo-Garcia et al., 
2004).  The empirical regimen of oral ciprofloxacin and oral  levofloxacin for treating AUC is 
250 mg twice daily for 3 days and 250 mg once a day for 3 days, respectively.  
7.2.5 β-lactam agents 
β-lactam agents that can be used to treat AUC include amoxicillin-clavulanate and oral 
second and third generation cephalosporins. Only amoxicillin-clavulanate will be described 
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in this chapter.  Amoxicillin inhibits bacterial cell wall synthesis by binding to the penicillin-
binding proteins. Clavulanate inhibits β-lactamases that inactivate amoxicillin.  
Amoxicillin-clavulanate has a broad spectrum which covers Gram positive bacteria, 
including S. saprophyticus; and Gram negative bacteria, including E. coli and P. mirabilis. 
Most common side effects of amoxicillin-clavulanate are diarrhea, nausea, vomiting and 
skin rash. Serious side effects include C. difficile colitis and Stevens-Johnson syndrome.   
In a randomized, single-blind treatment trial of 370 women with AUC with either a 3-day 
regimen of amoxicillin-clavulanate vs a 3-day regimen of oral ciprofloxacin, Hooton et al. 
demonstrated that the former was not as effective as the latter for the treatment of AUC 
(Hooton et al., 2005). Therefore, the recommended empirical regimen for treating AUC with 
amoxicillin-clavulanate is 500/125 mg by mouth three times a day for a range of 3 to 5 days. 
7.3 Infectious Disease Society of America (IDSA) guidelines for treatment of 
uncomplicated urinary tract infections 
The 2010 updated International Clinical Practice Guidelines for the treatment of acute 
uncomplicated cystitis (AUC) and pyelonephritis in women was published in the March 1, 
2011 issue of Clinical Infectious Disease (Gupta et al., 2011). These guidelines were also 
endorsed by the European Society for Microbiology and Infectious Diseases. Table 5 
summarizes the treatment guidelines for acute uncomplicated cystitis. Table 6 indicates the 
retail price of antibiotics used in treating AUC. 
 
AGENT DOSE DURATION 
Nitrofurantoin monohydrate 100 mg BID 5 – 7 days 
Nitrofurantoin macrocrystal 100 mg BID 5 – 7 days 
Trimethoprim-
sulfamethoxazole 
160/800 mg BID 3 days 
Fosfomycin trometamol 3 g Single dose sachet 
Fluoroquinolones Dose varies by agent 3-day regimen 
Β-lactams Dose varies by agent 3-5 day regimen 
Table 5. Treatment guidelines for urinary tract infections published in 2010 by The 
Infectious Disease Society of America. 
 
Antibiotic Retail Price 
Nitrofurantoin monohydrate (100 mg twice daily ) 
$13.50 (5 days) 
$18.90 (7 days) 
Nitrofurantoin macrocrystal (100 mg twice daily) 
$19.00 (5 days) 
$26.13 (7 days) 
Trimethoprim-sulfamethoxazole (160/800 mg twice 
daily) 
$4.00 (3 days) 
Fosfomycin trometamol (3 g single-dose sachet) $50.86 (1 day) 
Ciprofloxacin (250 mg twice daily) $17.70 (3 days) 
Levofloxacin (25 mg once daily) $36.00 (3 days) 
Amoxicillin-clavulanate 
$13.80 (3 days) 
$23.00 (5 days) 
Prices derived from www.drugstore.com 
Table 6. Retail price in the United States for commonly used antibiotics to treat AUC. 
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7.4 Treatment of uncomplicated pyelonephritis 
The IDSA guidelines also recommend the following for management of acute 
uncomplicated pyelonephritis (Gupta et al., 2011). 
 A urine culture and susceptibility test should always be performed, and initial 
empirical therapy should be tailored to the infecting uropathogen.  
 Oral ciprofloxacin (500 mg twice daily) for 7 days, with or without an initial 400 mg 
dose of intravenous ciprofloxacin, is appropriate in patients not requiring 
hospitalization where the prevalence of resistance of community uropathogens to 
fluoroquinolones does not exceed 10%.  If the prevalence of fluoroquinolone resistance 
is thought to exceed 10%, an initial 1-time intravenous dose of a long-acting parenteral 
antimicrobial, such as 1 g of ceftriaxone or a consolidated 24-h dose of an 
aminoglycoside is recommended. 
 A once-daily oral fluoroquinolone, including ciprofloxacin (1000 mg extended release 
for 7 days) or levofloxacin (750mg for 5 days), is an appropriate choice for therapy in 
patients not requiring hospitalization where the prevalence of resistance of community 
uropathogens is not known to exceed 10%. 
 Oral trimethoprim-sulfamethoxazole (TMP/SMX) (160/800 mg twice-daily for 14 days) 
is appropriate if the uropathogen is known to be susceptible. If TMP/SMX is used when 
the susceptibility is not known, an initial intravenous dose of a long-acting parenteral 
antimicrobial, such as 1 g of ceftriaxone or a consolidated 24-hour dose of an 
aminoglycoside is recommended.  
 Oral β-lactam agents are less effective than other agents. If an oral β-lactam agent is 
used, an initial intravenous dose of a long-acting parenteral antimicrobial, such as 1g of 
ceftriaxone or a consolidated 24-hour dose of an aminoglycoside is recommended.  
 Cases requiring hospitalization should initially be treated with an intravenous 
antimicrobial regimen; such as a fluoroquinolone, an aminoglycoside with or without 
ampicillin, an extended-spectrum cephalosporin, or extended–spectrum penicillin with 
or without an aminoglycoside, or a carbapenem. The choice among these agents should 
be based on local resistance data, and the regimen should be tailored on the basis of 
susceptibility results.      
8. Prevention 
The prevention of UTIs can be classified into two categories, non-antimicrobial and 
antimicrobial strategies.  
8.1 Non antimicrobial strategy 
A large population-based case-control study conducted by Fihn, et al. demonstrated that use 
of condoms coated with the spermicide nonoxynol-9 during intercourse was associated with a 
higher incidence of urinary tract infection caused by E. coli in young women (Fihn et al., 1996). 
Hooton et al. also demonstrated in a prospective study that recent use of a diaphragm with 
spermicide was one of the independent risk factors for symptomatic UTI (Hooton et al., 1996). 
Thus, sexually active women should be advised to avoid spermicide use during intercourse.  
Postcoital voiding has been advocated as a positive behavioral modification to prevent UTI 
(Stamm, 2010). However, a population-based, prospective cohort study did not showed that 
postcoital voiding was associated with decreased incidents of acute cystitis after 
multivariable analysis (Jackson et al., 2004) 
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Other non-antimicrobial strategies to prevent acute UTI have been investigated. Cranberries 
and other berries containing proanthocyanidins was proven, in vitro, to prevent 
uropathogens such as E. coli from adhering to urinary epithelium ( Zafriri et al., 1989). 
Kontiokari et al. conducted an open, randomized controlled 12-month follow-up trial which 
showed that cranberry-lingonberry was more effective in reducing recurrence of UTI 
compared to lactobacillus GG drink or no intervention (Kontiokari et al., 2001). However, a 
recent double-blind, placebo-controlled study of the effects of cranberry on risk of recurring 
UTI study demonstrated that, among healthy college women with acute UTI, those drinking 
8 oz of 27% cranberry juice twice daily, did not experience a decrease in the 6-month 
incidence of a second UTI, compared with those drinking a placebo (Barbosa-Cesnik et al., 
2011).    
Use of lactobacillus-containing probiotics has been proposed for the prevention of UTI. 
However, a review article by Barrons et al concluded that use of lactobacillus for the 
prevention of UTI remain inconclusive and controversial ( Barrons et al., 2008).  
Although a randomized double-blind, placebo-controlled trial of a topically applied 
intravaginal estriol cream revealed that estriol was more effective in preventing recurrent 
UTI in postmenopausal women ( Raz & Stam, 1993), the use of low dose oral estrogen did 
not reduce frequency of UTI (Brown et al., 2001; Cardozo et al., 1998).    
In recent years, there has been great enthusiasm for the development of a vaccine to prevent 
UTIs because of the increasing resistance of uropathogens against antimicrobials and 
concerns for adverse reactions from antimicrobials. A double-blind study involved 75 
patients randomly assigned to either placebo or vaginal mucosal suppository vaccines. The 
vaccine suppositories contained 10 strains of heat-killed uropathogenic bacteria. The study 
demonstrated that vaginal suppository vaccines were effective in reducing recurrence of E. 
coli UTI compared to placebo (Hopkins, 2007). So far there is no licensed vaccine for 
prevention of UTIs available in the USA.  
8.2 Antimicrobial strategies (Dielubanza & Schaeffer, 2011; Foster, 2008)  
Antimicrobial prophylaxis is a more effective way to prevent recurrence of UTI. However, 
this strategy carries the potential of promoting resistance and development of adverse 
reactions.  
Low-dose continuous antimicrobial prophylaxis nitrofurantoin (100 mg daily), cephalexin 
(250 mg daily), and TMP-SMX (daily or 3 times a week) have been used successfully as low-
dose antimicrobial prophylaxis for women with frequent UTIs.    
Other strategies that were found to be effective in preventing recurrent UTI are postcoital 
prophylaxis and self-start therapy. Postcoital prophylaxis is appropriate for women who 
tend to develop UTI after intercourse.  A single dose of antibiotic is used following 
intercourse.  Self-start therapy is for women who are unwilling to take antibiotic 
continuously for prevention of recurrent UTI. By this method, the patient diagnoses UTI 
herself with a urine dipstick or by recognizing incipient UTI symptoms and starts a 3-day 
course of antibiotics immediately.    
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